1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Clinical outcomes and treatment effect in subjects in the ESCAPE trial with last seen healthy to randomization time of >5.5 hours
Outcome Intervention (n = 33) Control (n = 26) Risk Difference (Absolute) P Value Risk Ratio Unadjusted (95% CI)
mRS at 90 days, (median) (IQR) 3 (3) 4 (3) – .029^{^a} –
mRS 0–2 at 90 days 48.5% (16/33) 29.2% (7/24) 19.3% .178 1.7 (0.8–3.4)
mRS 0–1 at 90 days 39.3% (13/33) 20.1% (5/24) 18.6% .161 1.89 (0.8–4.6)
NIHSS score 0–2 at 90 days 45.5 (15/33) 13.6 (3/22) 31.8% .019 3.33 (1.1–10.2)
ICH any (all types) 48.5% (16/33) 11.5% (3/26) 36.9% .004 4.2 (1.4–12.9)
ICH symptomatic 0% 0% 0% 1.000 –
mTICI 2b-3 (EVT group) or mAOL 2–3 (control group)^{^b} 87.5% (28/32) 13.0% (3/23) 74.5% – –
Note:—mTICI indicates modified Thrombolysis in Cerebral Infarction score; mAOL, modified Arterial Occlusive Lesion score; EVT, endovascular treatment.
↵a Parametric test of medians.
↵b Reperfusion assessed as mTICI 2b–3 at end of EVT in the intervention group or as recanalization with mAOL score 2–3 on repeat CTA in the control group.